Candel therapeutics announces upcoming data presentations on its oncolytic viral immunotherapies

Needham, mass., nov. 01, 2021 (globe newswire) -- candel therapeutics, inc. (nasdaq: cadl), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced its participation in upcoming medical and scientific conferences. candel president and chief executive officer, paul peter tak, md, phd, fmedsci, and e. antonio chiocca, md, phd, faans, principal investigator for the can-3110 clinical trial, will present data and overviews pertaining to the company's oncolytic viral immunotherapies at the 13th international oncolytic virus conference. in addition, patrick y. wen, md, principal investigator, will present data on can-2409 from a phase 1 clinical trial in high-grade glioma at the 26th annual meeting of the society for neuro-oncology (sno).
CADL Ratings Summary
CADL Quant Ranking